Sulfonylureas remain an option in the management of Type 2 Diabetes. In 2026, their role is more individualized because modern Diabetes care considers HbA1c reduction together with Hypoglycemia risk, Weight Gain, cardiovascular and kidney disease, cost, access and patient preferences.
What Are Sulfonylureas?
Sulfonylureas stimulate pancreatic beta cells to release Insulin. Common examples include Glimepiride, Gliclazide and Glipizide. Their glucose-lowering effect can be effective, but increased Insulin release can also cause Hypoglycemia.
Are Sulfonylureas Still Used in 2026?
Yes. The ADA Standards of Care in Diabetes—2026 continues to include Sulfonylureas among glucose-lowering medicines. Treatment selection should be person-centered and consider glycemic efficacy, Hypoglycemia risk, weight effects, cardiovascular and kidney outcomes, adverse effects, cost and access.
Advantages of Sulfonylureas
- Effective glucose lowering.
- Oral tablet treatment.
- Low cost and broad availability.
- Long clinical experience.
Main Limitations
Hypoglycemia
Hypoglycemia is the most important limitation, particularly in older adults, people with irregular meal patterns, kidney impairment or multiple glucose-lowering medicines.
Weight Gain
Sulfonylureas can be associated with Weight Gain. This can be undesirable when Obesity or Weight Loss is an important treatment goal.
Cardiovascular and Kidney Considerations
Unlike selected SGLT2 Inhibitors and GLP-1 Receptor Agonists, Sulfonylureas are not generally selected for independent cardiovascular or kidney protection.
How Do They Compare With Newer Diabetes Medicines?
Modern Diabetes treatment may include Metformin, SGLT2 Inhibitors, GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists. The appropriate choice depends on the individual’s clinical profile.
When Can a Sulfonylurea Still Make Sense?
A Sulfonylurea may be considered when an effective, affordable oral medicine is needed and the patient’s Hypoglycemia risk is acceptable. It can also be useful when newer medicines are unavailable, unsuitable or not tolerated. Treatment should be reviewed periodically rather than continued automatically.
Sulfonylureas in Combination Therapy
When another glucose-lowering medicine is added, the need for a Sulfonylurea and its dose should be reassessed if Hypoglycemia risk increases. This is particularly relevant when Sulfonylureas are combined with Insulin or other therapies that can lower glucose.
Glimepiride, Gliclazide and Glipizide
Choice among Sulfonylureas depends on age, kidney function, meal pattern, concurrent medicines and Hypoglycemia risk. In chronic kidney disease, conservative dosing and careful selection are particularly important. ADA 2026 notes that Glyburide is generally not recommended in chronic kidney disease, while Glipizide and Glimepiride should be initiated conservatively in patients at risk for Hypoglycemia.
Related Diabetes Articles
Metformin for Diabetes: Benefits, Side Effects, Dose and Who Should Take It
GLP-1 Medicines in 2026: Benefits, Weight Loss and Safety Guide
Key Takeaway
Sulfonylureas have not disappeared from modern Diabetes care. Their role has changed: they are now one option within an individualized treatment strategy. Their low cost and effective glucose lowering can be useful, while Hypoglycemia and Weight Gain require careful consideration.
Current Guideline
Consult an Endocrinologist in Ahmedabad
Dr. Moxit Shah, DM Endocrinology
Vishuddha Endocrine Clinic
104–105, Elite Magnum, Bhuyangdev Cross Road, Ahmedabad
Call / WhatsApp: +91 99799 92797
Google Business Profile: View Vishuddha Endocrine Clinic on Google
Medical Disclaimer: This article is for general educational information and does not replace an individual medical consultation. Diabetes medicines should be prescribed and adjusted according to individual clinical circumstances.
